Latest News in the pharma Industry

Research & Development

FDA grants accelerated approval to first drug for Duchenne muscular dystrophy

FDA grants accelerated approval to first drug for Duchenne muscular dystrophy

19 Sep 2016

Approval given to EXONDYS 51 (eteplirsen) as a once weekly intravenous infusion of 30 mg/kg for the treatment of DMD in patients who have a confirmed mutation in the DMD gene that is amenable to exon 51 skipping.

Read more 
Phase III combination trial of Bydureon and Farxiga shows significant blood sugar reduction in patients with type 2 diabetes

Phase III combination trial of Bydureon and Farxiga shows significant blood sugar reduction in patients with type 2 diabetes

18 Sep 2016

This was the first clinical trial to combine these two different anti-diabetes medicines, a GLP-1 receptor agonist and an SGLT-2 inhibitor, as an addition to standard-of-care therapy to evaluate potential benefits for patients with type 2 diabetes with...

Read more 
GSK's candidate shingles vaccine shows high efficacy against shingles

GSK's candidate shingles vaccine shows high efficacy against shingles

15 Sep 2016

Company expects to start submitting regulatory applications for the candidate vaccine for the prevention of shingles in people 50 years and above later this year.

Read more 
High-capacity nanoparticle for targeted cancer therapy

High-capacity nanoparticle for targeted cancer therapy

15 Sep 2016

MIT chemists have now shown they can package three or more drugs into a novel type of nanoparticle, allowing them to design custom combination therapies for cancer.

Read more 
AmpliPhi Biosciences’ bacteriophage cocktail shown to prevent C. difficile biofilm formation and reduce colonization

AmpliPhi Biosciences’ bacteriophage cocktail shown to prevent C. difficile biofilm formation and reduce colonization

13 Sep 2016

The data support the company's phage cocktails products' great potential as effective therapies to treat antibiotic resistant and difficult-to-treat infections.

Read more 
Horizon Discovery licenses biomanufacturing cell lines to CPI and NIBRT

Horizon Discovery licenses biomanufacturing cell lines to CPI and NIBRT

13 Sep 2016

This agreement allows any organisation, through CPI or NIBRT, to access Horizon’s biomanufacturing cell lines for research purposes.

Read more 
Santalis Pharmaceuticals issued patent for the use of sandalwood oil to treat cancers

Santalis Pharmaceuticals issued patent for the use of sandalwood oil to treat cancers

12 Sep 2016

Patent covers East Indian sandalwood oil-containing compositions that can be used to treat a variety of cancers.

Read more 
Orphan Drug Designation granted to nintedanib for treatment of systemic sclerosis

Orphan Drug Designation granted to nintedanib for treatment of systemic sclerosis

9 Sep 2016

Designation also includes the associated interstitial lung disease.

Read more 
AstraZeneca's first biologic respiratory medicine shows positive results in severe asthma

AstraZeneca's first biologic respiratory medicine shows positive results in severe asthma

8 Sep 2016

Benralizumab Phase III trials met primary and key secondary endpoints.

Read more 
Demand for Aquila BioMedica's specialist CRO services accelerates company expansion

Demand for Aquila BioMedica's specialist CRO services accelerates company expansion

7 Sep 2016

Company's immuno-oncology and histology services have allowed clients' go/no-go decisions to be made earlier in the drug development process and ultimately reduce clinical attrition.

Read more 
Non-drug device reduces COPD exacerbations - real-world study presented at ERS

Non-drug device reduces COPD exacerbations - real-world study presented at ERS

7 Sep 2016

The Aerobika device demonstrated a clinically-significant reduction in exacerbations in as little as 30 days of treatment, when used as an add-on to usual COPD medications.

Read more 
New findings confirm Ultibro Breezhaler consistently more effective than Seretide in reducing COPD flare-ups

New findings confirm Ultibro Breezhaler consistently more effective than Seretide in reducing COPD flare-ups

5 Sep 2016

Ultibro Breezhaler reduced rate of all COPD exacerbations across different patient sub-groups vs Seretide in new analyses from FLAME study.

Read more